Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease

Acta Neurologica Scandinavica

Volumn 122, Issue 4, 2010, Pages 270-277

  Wesnes, K ^a   Edgar, C ^b,h   Andreasen, N ^c   Annas, P ^d   Basun, H ^e   Lannfelt, L ^e   Zetterberg, H ^f   Blennow, K ^f   Minthon, L ^g  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Clinical Trials Consultant   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g LUND UNIVERSITY   (Sweden)

^h NONE   (United Kingdom)

Author keywords

Alzheimer's disease; Alzheimer's disease assessment scale cognitive subscale; cognition; cognitive drug research system; computerized; mini mental state examination

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE; TAU PROTEIN;

ALERTNESS; ALZHEIMER DISEASE; ARTICLE; ATTENTION; CEREBROSPINAL FLUID ANALYSIS; COGNITION; COMPUTER; CONCURRENT VALIDITY; DISEASE SEVERITY; EPISODIC MEMORY; HUMAN; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; PSYCHOMETRY; PSYCHOMOTOR PERFORMANCE; RESPONSE TIME; VALIDITY; WORD RECOGNITION; WORKING MEMORY;

ALZHEIMER DISEASE; ATTENTION; CHOLINESTERASE INHIBITORS; COGNITION; FEMALE; HUMANS; MALE; MEMORY; NEUROPSYCHOLOGICAL TESTS; PSYCHOMETRICS; PSYCHOMOTOR PERFORMANCE; REPRODUCIBILITY OF RESULTS;

EID: 77956413330     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2009.01309.x     Document Type: Article

References (42)

1. Folstein MF, Folstein SE, Mchugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 12 : 189 198.
2. Han L, Cole M, Bellavance F, Mccusker J, Primeau F. Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis. Int Psychogeriatr 2000 12 : 231 247.
3. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984 141 : 1356 1364.
4. Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 2007 64 : 1323 1329.
5. Connor DJ, Sabbagh MN. Administration and scoring variance on the ADAS-Cog. J Alzheimers Dis 2008 15 : 461 464.
6. CPMP. Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias http://www.emea.europa.eu/pdfs/human/ewp/055395en. pdf (accessed on 28 May, 2009).
7. Jacobs D, Sano M, Marder K et al. Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology 1994 44 : 1215 1220.
8. Mitnitski AB, Graham JE, Mogilner AJ, Rockwood K. The rate of decline in function in Alzheimer's disease and other dementias. J Gerontol A Biol Sci Med Sci 1999 54 : M65 9.
9. Seltzer B, Zolnouni P, Nunez M et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 2004 61 : 1852 1856.
10. Kurz A, Farlow M, Quarg P, Spiegel R. Disease stage in Alzheimer disease and treatment effects of rivastigmine. Alzheimer Dis Assoc Disord 2004 18 : 123 128.
11. Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004 75 : 677 685.
12. Doraiswamy PM, Kaiser L, Bieber F, Garman RL. The Alzheimer's disease assessment scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer Dis Assoc Disord 2001 15 : 174 183.
13. Gold M. Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease. J Clin Psychiatry 2007 68 : 430 438.
14. Schneider L, Dagerman K, Shaikh Z, Insel P. No secular trend and high variability for ADAS-cog change among placebo groups from clinical trials. Alzheimer's Dement. 2008 4 : T167.
15. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GR. The cognitive drug research computerised assessment system for demented subjects: a validation study. Int J Geriatr Psychiatr 1991 6 : 95 102.
16. Wesnes KA, Ward T, Mcginty A, Petrini O. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology (Berl) 2000 152 : 353 361.
17. Wesnes KA, Mckeith IG, Ferrara R et al. Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 2002 13 : 183 192.
18. Vellas B, Cunha L, Gertz HJ et al. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. Curr Med Res Opin 2005 21 : 1423 1429.
19. Galvin JE, Cornblatt B, Newhouse P et al. Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil. Alzheimer Dis Assoc Disord 2008 22 : 30 8.
20. Ferris SH, Lucca U, Mohs R et al. Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997 11 (Suppl. 3 34 8.
21. Blennow K, Zetterberg H, Minthon L et al. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett 2007 419 : 18 22. (Pubitemid 46694097)
22. Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 2004 566 : 261 269.
23. Degerman Gunnarsson M, Kilander L, Basun H, Lannfelt L. Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 2007 24 : 247 252.
24. Wiig EH, Nielsen NP, Minthon L, Warkentin S. A quick test of cognitive speed (AQT). San Antonio, TX, USA : Harcourt Assessment, 2002.
25. Sahakian BJ, Owen AM, Morant NJ et al. Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology (Berl) 1993 110 : 395 401.
26. Swainson R, Hodges JR, Galton CJ et al. Early detection and differential diagnosis of Alzheimer's disease and depression with neuropsychological tasks. Dement Geriatr Cogn Disord 2001 12 : 265 280.
27. Wesnes K, Pincock C. Practice effects on cognitive tasks: a major problem? Lancet Neurol 2002 1 : 473.
28. Wiig EH, Annas P, Basun H et al. The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease. Acta Neurol Scand, in press [Epub ahead of print].
29. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006 CD005593.
30. Clark CM, Sheppard L, Fillenbaum GG et al. Variability in annual Mini-mental state examination score in patients with probable Alzheimer disease: a clinical perspective of data from the consortium to establish a Registry for Alzheimer's disease. Arch Neurol 1999 56 : 857 862.
31. Dufouil C, Clayton D, Brayne C et al. Population norms for the MMSE in the very old: estimates based on longitudinal data. Mini-mental state examination. Neurology 2000 55 : 1609 1613.
32. Mohs RC, Schmeidler J, Aryan M. Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease. Stat Med 2000 19 : 1401 1409.
33. Grundman M, Petersen RC, Ferris SH et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 2004 61 : 59 66.
34. Wesnes K, Harrison J, Edgar C, Pincock C. The sensitivity and reliability of the cognitive drug research computerised cognitive assessment system to disease progression and treatment response in Alzheimer's disease. Paper presented at: International Psychogeriatric Association 12th International Congress, Stockholm, Sweden 2005 17 : 154.
35. Mohr E, Walker D, Randolph C, Sampson M, Mendis T. Utility of clinical trial batteries in the measurement of Alzheimer's and Huntington's dementia. Int Psychogeriatr 1996 8 : 397 411.
36. Walker MP, Ayre GA, Cummings JL et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. Neurology 2000 54 : 1616 1625.
37. Ballard CG, Aarsland D, Mckeith I et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 2002 59 : 1714 1720.
38. Allain H, Neuman E, Malbezin M et al. Bridging study of S12024 in 53 in-patients with Alzheimer's disease. J Am Geriatr Soc 1997 45 : 125 126.
39. Mckeith I, Del Ser T, Spano P et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000 356 : 2031 2036.
40. Verhey FR, Houx P, Van Lang N et al. Cross-national comparison and validation of the Alzheimer's disease assessment scale: results from the European Harmonization Project for Instruments in Dementia (EURO-HARPID). Int J Geriatr Psychiatry 2004 19 : 41 50.
41. Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007 6 : 734 746.
42. Collerton J, Collerton D, Arai Y et al. A comparison of computerized and pencil-and-paper tasks in assessing cognitive function in community-dwelling older people in the Newcastle 85+ Pilot Study. J Am Geriatr Soc 2007 55 : 1630 1635.